Therapeutic strategies harnessing the immune system to eliminate tumour cells have been
successfully used for several cancer types, including in patients with advanced-stage non …

Importance To date, no meta-analyses have comprehensively assessed the association of
neoadjuvant chemoimmunotherapy with clinical outcomes in non–small cell lung cancer …

Background Standard treatment with neoadjuvant nivolumab plus chemotherapy
significantly improves outcomes in patients with resectable non–small-cell lung cancer …

The use of neoadjuvant or perioperative anti-PD (L) 1 was recently tested in multiple clinical
trials. We performed a systematic review and meta-analysis of randomised trials comparing …

The treatment landscape of resectable early-stage non-small cell lung cancer (NSCLC) is
transforming due to the approval of novel adjuvant and neoadjuvant systemic treatments …

The treatment landscape of resectable early-stage non-small cell lung cancer (NSCLC) is
set to change significantly due to encouraging results from randomized trials evaluating …

About one third of patients with Non-Small Cell Lung Cancer (NSCLC) present at diagnosis
with localized or locally advanced disease amenable to curative surgical resection. Surgical …

Numerous treatment options are currently available to reduce the risk of recurrence in
patients with early-stage resectable non–small-cell lung cancer (NSCLC). These …

Background Neoadjuvant nivolumab plus chemotherapy significantly improved event-free
survival (EFS) and pathologic complete response (pCR) versus chemotherapy alone in …

Simple Summary The recent evidence shows that patients with resectable non-small cell
lung cancer (NSCLC) benefit from the addition of immunotherapy to chemotherapy before …